Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Reference Guide
  /  
H. pylori Virulence Factor iceA
Sign up free to test for 
H. pylori Virulence Factor iceA
.
One login for 30+ lab companies.

H. pylori Virulence Factor iceA

Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium that infects the stomach lining, causing chronic gastritis, peptic ulcers, and increasing the risk of gastric lymphoma and carcinoma. 

It is one of the most common chronic bacterial infections worldwide, affecting up to 50% of the global population, with higher prevalence in developing countries. 

H. pylori is typically acquired in early childhood and can persist without treatment. The bacterium's ability to survive in the acidic environment of the stomach is attributed to various virulence factors. 

Its high mutation and recombination rates lead to extensive strain diversity. 

While many infected individuals remain asymptomatic, H. pylori can cause symptoms such as abdominal pain, nausea, vomiting, and dyspepsia when gastritis or peptic ulcer disease develops. 

Diagnosis involves non-invasive methods like urea breath tests and stool antigen tests, and invasive methods such as endoscopic biopsy.   Treatment generally includes a combination of proton pump inhibitors and antibiotics. 

The iceA (induced by contact with epithelium) gene has two main allelic variants, iceA1 and iceA2. 

The iceA1 allele has been associated with increased mucosal inflammation and an elevated risk of peptic ulcer disease, while the iceA2 allele may have an inverse or protective association with peptic ulcers. 

However, the role and clinical relevance of iceA remains controversial, with conflicting findings across different populations and geographic regions.  Further research is needed to fully elucidate the mechanisms and impact of iceA allelic variation on H. pylori pathogenesis and disease outcomes.

What is H. Pylori?  [9., 10.]

Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium that infects the stomach lining and is a common cause of chronic gastritis, peptic ulcers, gastric lymphoma, and gastric carcinoma. 

It affects up to 50% of the global population, with higher prevalence in developing countries.  It is one of the most common chronic bacterial infections worldwide.

H. pylori is typically acquired in early childhood and persists without treatment. 

It is able to survive in the harsh acidic environment of the stomach due to its unique features like flagella for motility and urease enzyme production.

Its genome exhibits high mutation and recombination rates, leading to extensive strain diversity.  [9., 13.] 

While many infected individuals remain asymptomatic, the bacteria can cause symptoms such as abdominal pain, nausea, vomiting, and dyspepsia once gastritis or peptic ulcer disease develops.   H. pylori infection causes chronic gastritis in all cases and increases the risk of peptic ulcers by 2-6 fold and gastric cancer by 2-6 fold compared to uninfected individuals.  [5., 9.] 

Transmission occurs through fecal-oral, oral-oral, and gastric-oral routes, with lower socioeconomic status being a significant risk factor.  

Diagnosis involves both non-invasive methods like urea breath tests and stool antigen tests, and invasive methods such as endoscopic biopsy. 

Treatment often includes a combination of proton pump inhibitors and antibiotics.  Antibiotic combination therapies like clarithromycin triple therapy or bismuth quadruple therapy may be used.  [5.]  

Early identification and treatment of H. pylori infections are crucial to prevent serious gastrointestinal diseases and potential malignancies.  Collaboration among healthcare professionals is essential for effective management and improved patient outcomes.

What are H. pylori Virulence Factors?  [1., 4., 7.]

H. pylori virulence factors refer to the various bacterial components and mechanisms that enable the pathogen Helicobacter pylori to successfully colonize the human stomach, evade the host's immune defenses, and cause associated diseases and complications.

Colonization Factors

  • Urease enzyme: allows H. pylori to survive in the acidic environment of the stomach by producing ammonia to neutralize gastric acid
  • Flagella and chemotaxis: enables motility and directed movement towards the gastric epithelium for colonization

Adhesins:

  • BabA (Blood group antigen binding adhesin): binds to Lewis b antigens on gastric epithelial cells
  • SabA (Sialic acid-binding adhesin): binds to sialyl-Lewis x antigens
  • OipA (Outer inflammatory protein A): promotes inflammation and IL-8 production
  • Vacuolating cytotoxin (VacA): induces vacuolation and apoptosis in gastric epithelial cells
  • Cag Pathogenicity Island (cagPAI)/cagA:
  • Encodes a type IV secretion system (T4SS) to inject the CagA effector protein into host cells
  • CagA disrupts signaling pathways, causing cytoskeletal rearrangements and increased inflammation 

Other Factors

  • IceA (Induced by contact with epithelium): upregulated upon adherence, increases mucosal injury
  • DupA (Duodenal ulcer promoting gene A): associated with increased duodenal ulcer risk
  • GGT (Gamma-glutamyl transpeptidase): helps H. pylori persist by metabolizing glutamine and glutathione

H. pylori Virulence Factor iceA

The iceA gene, induced by contact with epithelium, has two allelic variants: iceA1 and iceA2. 

The iceA1 variant is associated with increased mucosal interleukin (IL)-8 expression and acute antral inflammation.  However, its role remains controversial as subsequent studies failed to reproduce these findings in different populations.  [12.]

The iceA1 allele is predominantly present in patients with duodenal ulcer (68.8%), while the iceA2 allele is more common in those with chronic gastritis (66.6%).  [2.]

Both alleles are significantly associated with the cagA vacA s1m2 genotype, which is a common virulence factor in both chronic gastritis and duodenal ulcer. 

In chronic gastritis, the prevalent genotype is cagA vacA s1m2 iceA2, whereas in duodenal ulcer, it is cagA vacA s1m2 iceA1.  [2.] 

Genetic heterogeneity and geographic differences may explain these variations.

Virulence Factor IceA and Peptic Ulcer vs. Gastric Cancer

One meta-analysis revealed a significant association between iceA1 and peptic ulcer (OR = 1.26).  Sensitivity analysis confirmed this association, with no publication bias detected.  [12.]

Subgroup analysis by geographic region showed higher iceA1 prevalence in Asian countries compared to Western countries.  IceA1 was significantly associated with duodenal ulcer (DU) but not with gastric ulcer (GU) or gastric cancer (GC).  [12.] 

However, the association between iceA alleles and gastric cancer risk is less clear and more controversial compared to peptic ulcers.  While some studies have found a higher prevalence of iceA1 among gastric cancer patients, others have reported no significant association between iceA status and gastric cancer risk.  [12.] 

There are conflicting findings on the role of iceA as a virulence factor for gastric cancer, with some studies suggesting that its effects could be influenced by other bacterial factors like cagA.  [12.]

In summary, the iceA1 allele shows a relatively consistent association with an increased risk of peptic ulcer disease across multiple studies.  However, its role in gastric cancer development remains controversial, with some studies finding an association but others reporting no significant link between iceA status and gastric cancer risk.

Laboratory Testing for H. pylori Virulence Factor iceA

Test Information, Sample Collection and Preparation

Laboratory testing for H. pylori virulence factors typically involves a stool sample, which is tested via polymerase chain reaction (PCR) for H. pylori virulence factors.

The stool sample may be collected at home.  While special preparation is not typically required for this assessment, other test components may require special preparation such as avoidance of certain foods, supplements or medications.

Click here to discover a laboratory test that assesses for H. pylori and virulence factors.  

Interpretation of Test Results

Optimal Levels of H. pylori Virulence Factor iceA

H. pylori infections can cause serious conditions including peptic ulcer disease and gastric cancer, and the presence of virulence factors such as the iceA virulence factor may increase the risk of developing peptic ulcer disease.  

Optimal levels of H. pylori virulence factor iceA are undetectable.

Clinical Significance of Elevated H. pylori Virulence Factor iceA

A positive test result indicates the presence of H. pylori and the virulence factor iceA, which requires prompt treatment.  

Treatments for H. pylori Infection

Typical first-line eradication therapies may include medications such as clarithromycin, bismuth, amoxicillin, metronidazole, or tetracycline in combination, along with a PPI.

The presence of iceA-positive strains may indicate the need for more intensive therapies, including anti-inflammatory and demulcent compounds, as some research has linked it with ulcer promotion.  [2., 12.] 

With the increase in antibiotic resistance demonstrated by H. pylori, especially in the setting of virulence factor-positive strains, scientists are exploring alternative methods of treating H. pylori including botanical therapies.  

Some botanical compounds that have shown promise in treating H. pylori include:  [6.] 

Terpenoids:

  • Monoterpenoids: compounds like limonene and β-pinene promote mucus secretion, reduce oxidative stress and inflammation, and inhibit NF-κB expression.
  • Limonene can be found in the peels and essential oils of oranges, lemons, limes, grapefruits, and mandarins as well as dill, caraway, mint and parsley.
  • Beta-pinene is a component of pine resin and is also found in various plants and herbs. Common sources include basil, parsley, rosemary, sage, as well as pine trees, fir trees, and other coniferous trees.
  • Sesquiterpenoids: found in cedarwood essential oil, they inhibit urease activity and H. pylori growth.
  • Triterpenoids: glycyrrhizic acid, found in Glycyrrhiza glabra or licorice, shows rapid anti-H. pylori properties.
  • Tetraterpenoids: Carotenoids like β-carotene and astaxanthin demonstrate antioxidant properties and reduce oxidative stress-mediated inflammation.
  • Beta-carotene is found in carrots, sweet potatoes, pumpkin, butternut squash, spinach, kale, collard greens, swiss chard, red and yellow peppers; mangoes, cantaloupe, apricot, papaya, peaches; cilantro, and parsley.  
  • Astaxanthin is found in seafood, some algae, and in supplement form.

Polyphenols:

  • Flavonoids: compounds like kaempferol and myricetin inhibit H. pylori growth, reduce urease activity, and exert anti-inflammatory effects.
  • Kaempferol can be found in many foods and essential oils including leafy greens, cruciferous vegetables such as broccoli, brussels sprouts and cabbage; herbs including dill, chives and tarragon; berries, capers and beans.  
  • Myricetin can be found in berries, especially cranberries; grapes, pomegranates, onions, kale, spinach, parsley, thyme, and walnuts.  
  • Tannoids: these compounds damage the bacterial membrane and reduce nitric oxide levels, exerting anti-inflammatory effects.

Alkaloids:

  • Berberine and Coptisine: these alkaloids inhibit urease activity and disrupt bacterial cell membranes, enhancing the effects of antibiotics.
  • Curcumin: curcumin, derived from turmeric, has shown efficacy in reducing H. pylori colonization, modulating immune responses, and improving symptoms of dyspepsia.

Related Biomarkers for H. pylori Virulence Factor iceA

In addition to the iceA virulence factor, several other biomarkers have been identified and studied in the context of H. pylori infection and associated gastric diseases.

CagA Virulence Factor and its Role in Gastric Cancer  [1., 4.]

The cytotoxin-associated gene A (CagA) is a major virulence factor of H. pylori that has been extensively studied for its role in gastric cancer development. 

The presence of CagA has been strongly associated with an increased risk of gastric cancer.  

BabA Virulence Factor and its Role in Gastric Cancer  [1.]

In Western countries, infection with BabA-producing strains is associated with an increased risk of peptic ulcer disease.

A recent study indicated that BabA-positive H. pylori strains have a higher adherence to epithelial cells and are often found in pediatric ulcerogenic H. pylori strains.

BabA-positive H. pylori strains can be classified as "specialists," which bind only blood group O-specific glycans, or "generalists," which bind glycans of blood groups O, A, and B.

The ability of these strains to bind specifically to blood group O glycans explains why individuals with blood group O are at a higher risk for developing duodenal ulcers.

VacA Virulence Factor and its Association with Peptic Ulcers  [4.] 

The vacuolating cytotoxin A (VacA) is another important virulence factor of H. pylori that contributes to the pathogenesis of peptic ulcers.  VacA induces the formation of vacuoles in gastric epithelial cells, leading to cellular damage and disruption of the gastric mucosal barrier. 

The presence of the vacA gene and its specific allelic variations have been linked to an increased risk of peptic ulcer disease and gastric inflammation.

Serological Biomarkers (Anti-H. pylori Antibodies)

In addition to bacterial virulence factors, serological biomarkers such as anti-H. pylori antibodies can also be used for the diagnosis and monitoring of H. pylori infection. 

These antibodies are produced by the host's immune system in response to the bacterial antigens and can be detected in serum or plasma samples.

Order H. pylori and Virulence Factor Testing

Click here to compare testing options and order tests for H. pylori.

What's 
H. pylori Virulence Factor iceA
?
If Your Levels Are High
Symptoms of High Levels
If Your Levels are Low
Symptoms of Low Levels

Hey Practitioners! On December 11th, join Dr. Terry Wahls in a free live class where she'll share her groundbreaking methods for managing MS and autoimmune patients. This live session will address your most pressing questions and will take a closer look at treatment options beyond the conventional standards of care. Register here.

Register Here
See References

[1.] Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019 Nov 19;11(11):677. doi: 10.3390/toxins11110677. PMID: 31752394; PMCID: PMC6891454.

[2.] Caner V, Yilmaz M, Yonetci N, Zencir S, Karagenc N, Kaleli I, Bagci H. H pylori iceA alleles are disease-specific virulence factors. World J Gastroenterol. 2007 May 14;13(18):2581-5. doi: 10.3748/wjg.v13.i18.2581. PMID: 17552005; PMCID: PMC4146818.

[3.] Chakrani, Z., Robinson, K. & Taye, B. Association Between ABO Blood Groups and Helicobacter pylori Infection: A Meta-Analysis. Sci Rep 8, 17604 (2018). https://doi.org/10.1038/s41598-018-36006-x

[4.] Chang, WL., Yeh, YC. & Sheu, BS. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. J Biomed Sci 25, 68 (2018). https://doi.org/10.1186/s12929-018-0466-9

[5.] Connor B. Helicobacter Pylori | CDC Yellow Book 2024. wwwnc.cdc.gov. Published 2024. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/helicobacter-pylori

[6.] Deng R, Chen X, Zhao S, Zhang Q, Shi Y. The effects and mechanisms of natural products on Helicobacter pylori eradication. Frontiers in cellular and infection microbiology. 2024;14. doi:https://doi.org/10.3389/fcimb.2024.1360852

[7.] Donelli LC Gianfranco. Virulence Factors of Helicobacter pylori. Microbial Ecology in Health and Disease. 2000;12(2):259-262. doi:https://doi.org/10.1080/089106000750060512

[8.] Doohan D, Rezkitha YAA, Waskito LA, Yamaoka Y, Miftahussurur M. Helicobacter pylori BabA–SabA Key Roles in the Adherence Phase: The Synergic Mechanism for Successful Colonization and Disease Development. Toxins. 2021;13(7):485. doi:https://doi.org/10.3390/toxins13070485

[9.] Malfertheiner, P., Camargo, M.C., El-Omar, E. et al. Helicobacter pylori infection. Nat Rev Dis Primers 9, 19 (2023). https://doi.org/10.1038/s41572-023-00431-8

[10.] Parikh NS, Ahlawat R. Helicobacter Pylori. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534233/

[11.] Shiota S, Suzuki R, Yamaoka Y. The significance of virulence factors in Helicobacter pylori. J Dig Dis. 2013 Jul;14(7):341-9. doi: 10.1111/1751-2980.12054. PMID: 23452293; PMCID: PMC3721066.

[12.] Shiota S, Watada M, Matsunari O, Iwatani S, Suzuki R, Yamaoka Y. Helicobacter pylori iceA, Clinical Outcomes, and Correlation with cagA: A Meta-Analysis. Katoh M, ed. PLoS ONE. 2012;7(1):e30354. doi:https://doi.org/10.1371/journal.pone.0030354

[13.] Thorell, K., Muñoz-Ramírez, Z.Y., Wang, D. et al. The Helicobacter pylori Genome Project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes. Nat Commun 14, 8184 (2023). https://doi.org/10.1038/s41467-023-43562-y

Test for

H. pylori Virulence Factor iceA

Order, track, and receive results from 30+ labs in one place.